Santaris Pharma Raises $30 Million

Santaris Pharma, a Danish biopharmaceutical company, has completed a EUR 20.4 million ($30 million) private investment round. Gilde Healthcare Partners, a new investor, contributed EUR 7.5 million of the financing, with the rest coming from an international syndicate of existing investors, including BankInvest, Forbion Capital Partners, Global Life Science Venture, Innovation Capital, Novo LD, Omega, Seventure, Sunstone Capital, and members of the company's board and management. www.santaris.com